Avalo Therapeutics, Inc.
AVTX · Nasdaq · United States
Share price · AVTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AVTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+18.9%
Nothing announced by AVTX that day or the session before.
- 22 Oct 2026-39.2%
Nothing announced by AVTX that day or the session before.
- 13 Oct 2026-9.3%
Nothing announced by AVTX that day or the session before.
- 6 May 2026+34.1%
- 5 May 2026+18.0%
- 28 Apr 2026-10.8%
- 16 Apr 2026+8.0%
Nothing announced by AVTX that day or the session before.
- 8 Apr 2026-9.5%
Nothing announced by AVTX that day or the session before.
- 6 Apr 2026-8.4%
Nothing announced by AVTX that day or the session before.
- 1 Apr 2026+11.9%
Nothing announced by AVTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of AVTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | IL-1 betaMonoclonal antibody | Hidradenitis Suppurativa | |
QuisovalimabNo recent activity | Phase 2 | LIGHT (TNFSF14)Monoclonal antibody | Asthma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $15M | $65M+ $328M short-term inv. | $19M-$12M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $23M | $86M+ $315M short-term inv. | $36M-$20M operating cash flow | report ↗ |
| 2026-Q1 | — | $14M | $25M+ $57M short-term inv. | $20M-$18M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $14M | $27M+ $85M short-term inv. | $31M-$16M operating cash flow | report ↗ |
| 2025-Q2 | — | $14M | $43M+ $71M short-term inv. | $21M-$11M operating cash flow | report ↗ |
| 2025-Q1 | — | $9.1M | $125M | $13M-$9.5M operating cash flow | report ↗ |
| 2024-Q3 | $0.3M | $9.5M | $82M | —-$12M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $4.6M | $94M | —-$16M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $2.1M | $110M | $121M-$6.2M operating cash flow | report ↗ |
| 2023-Q3 | $0.2M | $1.3M | $10M | $5.2M-$6.8M operating cash flow | report ↗ |
| 2023-Q2 | $0.6M | $4.7M | $6.5M | $8.2M-$11M operating cash flow | report ↗ |
| 2023-Q1 | $0.5M | $6.0M | $17M | $10.0M-$10M operating cash flow | report ↗ |
| 2022-Q3 | $15M | $7.0M | $17M | —$5.7M operating cash flow | report ↗ |
| 2022-Q2 | $1.0M | $8.5M | $11M | $13M-$12M operating cash flow | report ↗ |
| 2022-Q1 | $1.2M | $9.6M | $39M | $22M-$16M operating cash flow | report ↗ |
| 2021-Q3 | $1.4M | $11M | $72M | $17M-$16M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.1M | $50M | $16M+ $82M short-term inv. | $20M-$51M operating cash flow | report ↗ |
Avalo Therapeutics reported FY2025 revenue of $0.06M, down 86.4% YoY, and R&D expenditures of $50.08M, up 104.9% YoY. Cash, cash equivalents and short-term investments totaled $98.3M at December 31, 2025, and the company reported a net loss of $78.26M for the year.
Management stated that current cash, cash equivalents and short-term investments are expected to fund operations into 2028. The key upcoming milestone is topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) in hidradenitis suppurativa, expected in the second quarter of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.4M | $24M | $135M+ $0 short-term inv. | $8.8M-$49M operating cash flow | report ↗ |
| 2023-FY | $1.9M | $14M | $7.5M | $7.9M-$31M operating cash flow | report ↗ |
| 2022-FY | $18M | $31M | $13M | $10M-$27M operating cash flow | report ↗ |
| 2021-FY | $5.4M | $60M | $55M | $21M-$71M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 41 sales ($8.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-30 | Philip Ron M · director | Award / grant (derivative) | 1,109 | $12.29 | $14K | Form 4 |
| 2026-09-30 | Lind Kevin Robert · director | Award / grant (derivative) | 1,352 | $12.29 | $17K | Form 4 |
| 2026-09-30 | Jain Rita · director | Award / grant (derivative) | 1,322 | $12.29 | $16K | Form 4 |
| 2026-09-16 | Sullivan Christopher Ryan · Chief Financial Officer | Option exercise | 12,394 | $9.88 | $122K | Form 4 |
| 2026-09-16 | Sullivan Christopher Ryan · Chief Financial Officer | Open-market sale | 12,394 | $16.33 | $202K | Form 4 |
| 2026-09-16 | Sullivan Christopher Ryan · Chief Financial Officer | Option exercise (derivative) | 12,394 | — | — | Form 4 |
| 2026-09-10 | Sullivan Christopher Ryan · Chief Financial Officer | Option exercise | 10,185 | $8.04 | $82K | Form 4 |
| 2026-09-10 | Sullivan Christopher Ryan · Chief Financial Officer | Open-market sale | 10,185 | $17.62 | $179K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 97 reporting institutions held 31.2M shares ($433.2M, 54.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 2,879,481 | $43.0M |
| 2 | Caligan Partners LP | 1,635,023 | $24.4M |
| 3 | BVF INC/IL | 1,632,845 | $24.4M |
| 4 | Avoro Capital Advisors LLC | 1,410,000 | $21.1M |
| 5 | Affinity Asset Advisors, LLC | 1,340,840 | $20.0M |
| 6 | Nantahala Capital Management, LLC | 1,235,000 | $18.4M |
| 7 | UBS Group AG | 1,141,980 | $17.0M |
| 8 | Point72 Asset Management, L.P. | 916,142 | $13.7M |
| 9 | FARALLON CAPITAL MANAGEMENT LLC | 916,000 | $13.7M |
| 10 | RTW INVESTMENTS, LP | 856,962 | $12.8M |
| 11 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 854,000 | $12.8M |
| 12 | MILLENNIUM MANAGEMENT LLC | 835,484 | $12.5M |
| 13 | TCG Crossover Management, LLC | 738,383 | $11.0M |
| 14 | Balyasny Asset Management L.P. | 731,586 | $10.9M |
| 15 | VANGUARD CAPITAL MANAGEMENT LLC | 719,694 | $10.7M |